{
    "nct_id": "NCT05540340",
    "official_title": "Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation",
    "inclusion_criteria": "* Age18 - 79 years old\n* Diagnosed with any type of lymphoma [Hodgkin, non-Hodgkin (B- or T-cell)] and planned for BEAM-AHCT\n* KPS > 70\n* Cardiac ejection fraction of > 45%\n* Hemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of ≥45%\n* Creatinine clearance of ≥ 40 mL/min\n* Completion of most recent systemic therapy within 12 weeks of enrollment\n* Complete or partial response to systemic chemotherapy by IWG Working Group Criteria.\n* Total bilirubin < 2.0 mg/dL in the absence of suspected Gilbert's disease (if Gilbert's disease is suspected, the total bilirubin must be ≤3.0 mg/dL), and AST & ALT < 2.5 ULN.\n* Minimum stem cell dose of 2 x 10*6 CD34+ cells/kg\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Disease progression by IWG Working Group since last therapy\n* Pregnant or lactating females\n* Contraindication to CE melphalan or any of the required supportive treatments, including hypersensitivity to G-CSF or pegfilgrastim\n* Any known allergy or allergic reactions to Captisol\n* Any other medical condition or laboratory evaluation that, in the treating physician's or principal investigator's opinion, makes the patient unsuitable to participate in this clinical trial",
    "miscellaneous_criteria": ""
}